Treatment of extramammary Paget's disease with imiquimod in a real-life setting: a multicenter retrospective analysis in Spain.
Helena EscolàBeatriz LlombartAlba Escolà-RodríguezLucía Barchino-OrtizJoaquim MarcovalInmaculada AlcarazSònia Beà-ArdébolAgustí TollRomán Miñano-MedranoPedro Rodríguez-JiménezMaría López-NuñezCarla Ferrándiz-PulidoAne JakaEmili MasferrerRafael S Aguayo-OrtizMireia YébenesJorge Arandes-MarcocciVerónica Ruiz-SalasLucía Turrión-MerinoMiquel JustJúlia Sánchez-SchmidtLorena LealFátima Mayo-MartínezLara Haya-MartínezAlejandra Sandoval-ClavijoGiulia Greta DradiYolanda DelgadoJúlia Verdaguer-FajaDaniel López-CastilloRamon M PujolGustavo DezaPublished in: Clinical and experimental dermatology (2024)
Imiquimod appears as an effective therapeutic alternative for both first-line and previously treated EMPD lesions. However, a less favorable therapeutic response could be expected in larger lesions and those affecting >1 anatomical site. Based on our results, a 3-4 times weekly regimen of imiquimod with a treatment duration of at least 6 months could be considered an appropriate therapeutic strategy for EMPD patients.